1. Walter RB, Raden BW, Kamikura DM et al (2005) Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood 105:1295–1302
2. Thorpe PE, Wallace PM, Knowles PP et al (1987) New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo. Cancer Res 47:5924–5931
3. Thorpe PE, Wallace PM, Knowles PP et al (1988) Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages. Cancer Res 48:6396–6403
4. Xie H, Audette C, Hoffee M et al (2004) Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. J Pharmacol Exp Ther 308:1073–1082
5. Trail PA, Willner D, Lasch SJ et al (1993) Cure of xenografted humancarcinomas by BR96-doxorubicin immunoconjugates. Science 261:212–215